Antacids containing aluminum or magnesium, antidiarrheals, phenobarbital: Pos-sible pharmacokinetic alterations and subsequent decreased therapeutic response to chlorpro-mazine. Use together cautiously.
Antiarythmics, atropine, CNS depressants (such as analgesics; barbiturates; epidural, general, or spinal anesthetics; narcotics; tranquilizers), disopy-ramide, parenteral magne-sium sulfate, pro-cainamide, quinidine, other anticholinergia (such as antidepressants, MAO inhibitors): Additive ef-fects likely. Avoid use together.
Beta blockers: May inhibit chlorpromazine me-tabolism, increasing plasma levels and toxicity. Use together cautiously.
Bromocriptine: Drug may antagonize therapeu-tic effect of bromocriptine on prolactin secretion. Monitor patient closely.
Centrally acting antihypertensives, such as cloni-dine, guanabenz, guanadrel, guanethidine, methyldopa, reserpine: Chlorpromazine may in-hibit blood pressure response to these drugs. Monitor blood pressure.
Dopamine: Concomitant use may decrease vaso-constricting effects of high-dose dopamine; may decrease effectiveness and increase toxicity of levodopa (by dopamine blockade).Monitor pa-tient closely.
Epinephrine: Drug may cause epinephrine re-versal: the beta-adrenergic agonist activity of ep-inephrine is evident whereas its alpha effects are blocked, leading to decreased diastolic and in-creased systolic pressures and tachycardia. Use together cautiously.
Propylthiouracil: Increased risk of agranulocyto-sis. Monitor patient closely.
Sympathomimetics, such as appetite suppres-sants, ephedrine (often found in nasal sprays), epinephrine, phenylephrine,
phenylpropanolamine:May decrease stimulatory and pressor ef-fects of these drugs. Monitor patient closely.
Sun exposure: Photosensitivity reactions may re-sult. Advise parents to take precautions for the children being exposed. |